| News

Robots from Basel set to revolutionize surgery

27.07.2020

The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.

Robotic endoscope tip developed by the Miracle project (img: F. Brüderli)

The Miracle (Minimally Invasive Robot-Assisted Computer-guided LaserosteotomE) project is pursuing a number of different aims, as detailed in a press release issued by the University of Basel. These include planning an operation in virtual reality, high-precision bone cutting using a smart laser saw and using 3D-printed organic implants such as a new knee joint in a minimally invasive surgical procedure. The development of the individually configurable robot needed for these applications is being supported by the Werner Siemens Foundation, which has increased its funding for the project by 12 million Swiss francs to an overall total of 27 million Swiss francs

The additional funding will be used during the second phase of the Miracle project, when the technologies developed in the first phase will be combined within a modular robot. “We are deeply grateful to the Werner Siemens Foundation for supporting our visionary project”, comments Philippe Cattin, Co-Director of both Miracle project phases and head of the Department of Biomedical Engineering (DBE) at the University of Basel. The DBE is carrying out work related to the Miracle project at the Allschwil location of the Switzerland Innovation Park Basel Area, which is operated and managed by the investment and innovation promotion agency Basel Area Business & Innovation. Unique opportunities will now be presented to Basel in its role as an innovation location. “Thanks to this financing and our expertise, we are now able to tap into huge opportunities that will open the door for robotics in surgery”, Cattin explains.

The technology developed during the first phase of the project for the planning of operations in virtual reality is already being used today. In phase two, it is to be used to help design the shape and composition of implants, with the aim thereafter being to custom manufacture these implants via a 3D printer. Cattin is therefore sharing leadership of this phase with Florian M. Thieringer, who is head of the 3D Print Lab at University Hospital Basel. “With Miracle, we don’t just want to develop a new technology but rather fully transform bone surgery,” explains Hans-Florian Zeilhofer, surgeon and Delegate for Innovation at the University of Basel, who was also Co-Director of the first project phase together with Philippe Cattin.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Yokogawa establishes innovation center in Allschwil

The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel gains new biotech in Bright Peak

Versant Ventures has made a US$35 million Series A funding commitment to Bright Peak Therapeutics and has now announced the debut of this biotech. It will operate in Basel and San Diego.

Read More
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Robots from Basel set to revolutionize surgery

The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.

Read More
Basel Area Business & Innovation, Innovation

T3 Pharma raises over 25 million Swiss francs

T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.

Read More
Basel Area Business & Innovation, Innovation

Versameb raises 6 million Swiss francs

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Read More
Basel Area Business & Innovation, Innovation

Genedata accelerating drug development

Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.

Read More
1 2 3 32

Do you have a question? We'd like to hear from you.